Amgen Inc. (AMGN) CEO Bob Bradway on Q2 2022 Results - Earnings Call Transcript
Amgen Inc. (NASDAQ:AMGN) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET
Company Participants
Arvind Sood - VP, IR
Bob Bradway - Chairman and CEO
Peter Griffith - CFO
Murdo Gordon - EVP, Global Commercial Operations
David Reese - EVP, Research and Development
Conference Call Participants
Jay Olson - Oppenheimer
Chris Raymond - Piper Sandler
Salveen Richter - Goldman Sachs
Umer Raffat - Evercore ISI
Michael Yee - Jefferies
Matthew Harrison - Morgan Stanley
David Risinger - SVB Securities
Mohit Bansal - Wells Fargo
Geoff Meacham - Bank of America
Yaron Werber - Cowen
Carter Gould - Barclays
Evan Seigerman - BMO
Michael Schmidt - Guggenheim
Robyn Karnauskas - Truist
Dane Leone - Raymond James
Tim Anderson - Wolfe Research
Operator
My name is Jason and I'll be your conference facilitator today for Amgen's Second Quarter of 2022 Financial Results Conference Call. [Operator Instructions]
I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may now begin.
Arvind Sood
Okay, Jason, thank you. Good afternoon, everybody and welcome to our Q2 call.
Lots to cover today so we'll go and jump right in. Some of the key themes you'll hear about today include continued volume driven growth, our strategy of seeking both internal and external innovation, the latter exemplified by our announcement this morning of acquiring ChemoCentryx and lastly navigating through a difficult macro environment. We have posted the slides for your background, we will use non-GAAP financial measures in our presentation today, and some of the statements will be forward-looking. Our SEC filings identify factors that could cause our actual results to differ materially.
So with that, I would like to turn the call over to our Chairman and CEO, Bob Bradway. Bob?
Bob Bradway
Okay. Hello, everyone, and thank you for joining our call.
Today, we'll be discussing our second quarter performance, as well as our planned acquisition of ChemoCentryx which all of us here are very excited about. Starting with our operating results, we delivered strong volume driven growth in the second quarter, with unit volumes increasing 10%.
Our innovative products performed well globally. Repatha, Otezla, Prolia and EVENITY, all delivered double-digit sales growth in the quarter. Our KYPROLIS, Nplate and BLINCYTO in our innovative hematology oncology portfolio, all generated record quarterly sales.
Our two newest products LUMAKRAS and TEZSPIRE are both off to a strong start. LUMAKRAS is now being prescribed for patients with non-small cell lung cancer in 25 countries around the world. TEZSPIRE has made a big impact in a short period of time for a broad population of patients with severe asthma in the U.S.